Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind …
…, A Cats, MI Grootscholten, RA Dichmann… - The Lancet …, 2019 - thelancet.com
Background VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis
can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess …
can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess …
[HTML][HTML] Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US …
…, JJ Zoeller, GR Bean, R Dichmann… - Nature …, 2020 - nature.com
In this multicenter, open-label, randomized phase II investigator-sponsored neoadjuvant
trial with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials …
trial with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials …
Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain …
…, JA Taguchi, D Chan, RA Dichmann… - … in medical oncology, 2018 - journals.sagepub.com
Background: Improving outcomes for patients with human epidermal growth factor 2-positive
(HER2+) central nervous system (CNS) metastases remains an unmet clinical need. This …
(HER2+) central nervous system (CNS) metastases remains an unmet clinical need. This …
A phase I/II study of carfilzomib (CFZ) as a replacement for bortezomib (BTZ) for multiple myeloma (MM) patients (Pts) progressing while receiving a BTZ-containing …
JR Berenson, O Yellin, R Dichmann, D Patel-Donnelly… - 2012 - ascopubs.org
8098 Background: Recent data has shown that single-agent CFZ can produce responses
among MM pts refractory to previous treatment regimens including those containing BTZ. We …
among MM pts refractory to previous treatment regimens including those containing BTZ. We …
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with rituximab for previously treated …
GA Salles, TJ Ervin, R Dichmann, R Ramchandren… - 2014 - ascopubs.org
TPS8620 Background: PI3Kδ is critical for activation, proliferation and survival of B cells and
plays a role in homing and retention in lymphoid tissues. PI3Kδ signaling is hyperactive in …
plays a role in homing and retention in lymphoid tissues. PI3Kδ signaling is hyperactive in …
Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed …
JR Berenson, JD Hilger, R Dichmann… - 2013 - ascopubs.org
8599 Background: Recent data has shown that single-agent CFZ can produce responses
among MM pts refractory to previous treatment regimens including those containing BTZ. We …
among MM pts refractory to previous treatment regimens including those containing BTZ. We …
[HTML][HTML] A phase 1/2 study of carfilzomib as a replacement for bortezomib for multiple myeloma (MM) patients (pts) refractory to a bortezomib-containing combination …
JR Berenson, JD Hilger, R Dichmann… - Blood, 2012 - Elsevier
Abstract 4063 Background: Carfilzomib has shown promise in treating both newly diagnosed
and relapsed/refractory MM patients. Recent data has suggested that single agent …
and relapsed/refractory MM patients. Recent data has suggested that single agent …
[HTML][HTML] Abstract P4-07-01: Tumor expression and microenvironment in HER2-positive breast cancer before and on HER2-targeted therapy: Analysis of microarray …
…, J Dering, HW Chen, R Dichmann… - Cancer research …, 2020 - scholarship.miami.edu
Abstract P4-07-01: Tumor expression and microenvironment in HER2-positive breast cancer
before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO …
before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO …
[HTML][HTML] Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access …
PA Jänne, AJ Wozniak, CP Belani, ML Keohan… - Journal of Thoracic …, 2006 - Elsevier
Background In a randomized phase III trial, pemetrexed plus cisplatin was associated with
improved survival compared with cisplatin alone for patients with malignant pleural …
improved survival compared with cisplatin alone for patients with malignant pleural …
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access …
CK Obasaju, Z Ye, AJ Wozniak, CP Belani, ML Keohan… - Lung Cancer, 2007 - Elsevier
BACKGROUND: An expanded access program (EAP) provided patient access to pemetrexed
prior to its commercial availability. The current report consists of US patients in the EAP …
prior to its commercial availability. The current report consists of US patients in the EAP …